An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children

被引:7
作者
Lauvau, DVA [1 ]
Verbist, L [1 ]
Abrassart, C [1 ]
Adriaens, F [1 ]
Andre, F [1 ]
Bockaert, K [1 ]
Bodart, E [1 ]
Bricteux, G [1 ]
Casneuf, J [1 ]
Cassiers, M [1 ]
Chefneux, A [1 ]
DeNayer, J [1 ]
Dechamps, L [1 ]
Deurinck, M [1 ]
Devriendt, E [1 ]
Dockx, M [1 ]
Ehrentreich, U [1 ]
Fafchamps, Y [1 ]
Geuens, M [1 ]
Hecquet, T [1 ]
Hendrickx, G [1 ]
Israel, E [1 ]
Jadoul, R [1 ]
Krygier, A [1 ]
Lagasse, E [1 ]
Lamotte, PJ [1 ]
Legrand, B [1 ]
Lemahieu, R [1 ]
Malchair, R [1 ]
Maquet, JC [1 ]
Mertens, G [1 ]
Neufcoeur, JP [1 ]
Pieraert, C [1 ]
Pierquin, G [1 ]
Prudhomme, J [1 ]
Reginster, L [1 ]
Ureel, D [1 ]
VanBiervliet, JP [1 ]
VanDenNoortgaete, M [1 ]
VanMelkebeke, E [1 ]
Vandenbossche, L [1 ]
Verboven, M [1 ]
Vertruyen, A [1 ]
Zasinska, E [1 ]
Zeligzon, A [1 ]
机构
[1] ALGEMEEN ZIEKENHUIS ST VINCENTIUS, GHENT, BELGIUM
关键词
azithromycin; co-aimoxiclav; antibacterial; streptococcal pharyngitis; tonsillitis; bronchitis; pneumonia; children;
D O I
10.1177/030006059702500506
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
An open prospective, multicentre, comparative, randomized (2:1) study was conducted in 481 children diagnosed as having mild-to-moderate lower respiratory tract infections. The efficacy and safety of azithromycin suspension (10 mg/kg), dosed orally once daily for 3 days, was compared with that of co-amoxiclav (10 mg/kg in a 4:1 ratio), dosed orally three times daily for 5 - 10 days. The proportion of evaluable patients (n = 472) showing a cure or improvement was significantly higher in the azithromycin group (96.8%) than in the co-amoxiclav group (91%, P = 0.0199). There were six relapses in both groups, giving an overall response rate of 95% for azithromycin versus 87.1% for co-amoxiclav (P = 0.0025). Adverse events were reported in 10% of the patients treated with azithromycin, and 11.3% of co-amoxiclav patients. Reported and counted compliance was significantly better in the azithromycin group. A 3-day regimen of azithromycin was as effective and as safe as a 5 - 10 day regimen of co-amoxiclav in the treatment of respiratory tract infections in children, and compliance was improved.
引用
收藏
页码:285 / 295
页数:11
相关论文
共 14 条
  • [1] BALDWIN DR, 1990, EUR RESPIR J, V3, P886
  • [2] EFFECTS OF INTERVENTION ON ANTIBIOTIC COMPLIANCE IN PATIENTS IN GENERAL-PRACTICE
    COCKBURN, J
    REID, AL
    BOWMAN, JA
    SANSONFISHER, RW
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1987, 147 (07) : 324 - &
  • [3] Azithromycin - A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections
    Dunn, HJ
    Barradell, LB
    [J]. DRUGS, 1996, 51 (03) : 483 - 505
  • [4] GREENBERG RN, 1984, CLIN THER, V6, P592
  • [5] MULTICENTER EVALUATION OF AZITHROMYCIN AND PENICILLIN-V IN THE TREATMENT OF ACUTE STREPTOCOCCAL PHARYNGITIS AND TONSILLITIS IN CHILDREN
    HAMILL, J
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 : 89 - 94
  • [6] REASONS FOR FAILURES IN PENICILLIN TREATMENT OF STREPTOCOCCAL TONSILLITIS AND POSSIBLE ALTERNATIVES
    HOLM, SE
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (01) : S66 - S69
  • [7] MANFREDI R, 1992, J CHEMOTHERAPY, V4, P364
  • [8] Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis tonsillitis
    ODoherty, B
    Pilfors, G
    Quinn, PT
    Howard, A
    Bradbury, F
    Scully, M
    Clarke, O
    Kiernan, J
    Ryan, MF
    OKelly, P
    Williams, PA
    Khong, TK
    Hamill, JJ
    Burman, A
    Khatri, CP
    Agrawal, P
    Soares, P
    Hughes, I
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (09) : 718 - 724
  • [9] Powers JL, 1996, PEDIATR INFECT DIS J, V15, pS30
  • [10] PRINCIPI N, 1993, EUR J CLIN RES, V4, P127